Mission Biocapital — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Board seatCassidy Blundell· per SEC Form D
Co-investorsAlta PartnersLongwood FundDolby Family VenturesForbionService Provider Capital
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)PETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)CHRISTOPHER SILBER(Executive Officer)
Co-investorsCanaan PartnersF-Prime CapitalMonograph Capital PartnersOUP (Osage University Partners)Osage University Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.